Hotel Floor Plans

CONTINUING EDUCATION CREDIT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the Joint Providership of Professional Education Services Group/AffinityCE and the Pulmonary Hypertension Association. Professional Education Services Group is accredited by the ACCME to provide continuing medical education for physicians. Professional Education Services Group designates this live CME activity for a maximum of 16.0 hours of AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the Joint Providership of Professional Education Services Group/AffinityCE and the Pulmonary Hypertension Association. Professional Education Services Group is accredited by the ACCME to provide continuing medical education for physicians. Professional Education Services Group designates this live CME activity for a maximum of 16.0 hours of AMA PRA Category 1 Credit(s)™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

This educational activity is provided through a collaboration between Professional Education Services Group and The Pulmonary Hypertension Association. Professional Education Services Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 16.0 contact hours of nurse CE credit.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Professional Education Services Group/AffinityCE and the Pulmonary Hypertension Association. Professional Education Services Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 031105. This course is offered for 16.0 contact hours.

Respiratory Therapists

Professional Education Services Group is accredited as a provider of continuing education contact hours for respiratory therapists by the American Association for Respiratory Care. This Continuing Respiratory Care Education (CRCE) system of the American Association of Respiratory Care (AARC) grants approval for 16.0 hours for this course.

Pharmacists and Pharmacy Technicians

Professional Education Services Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based activity is approved for up to 16.0 (1.60 CEUs) of pharmacy continuing education credit. UAN are provided for each session. Participant CE records will be electronically communicated to CPE Monitor. The cost for pharmacy CE activities are included in Conference registration fees.

Social Workers

This program is approved by the National Association of Social Workers for up to 13.0 Social Work continuing education contact hours.

Other Professionals

Other professionals participating in this activity may obtain a General Participation Certificate indicating their participation and the number of hours of continuing education credit. This certificate may be used as a record of continuing education participation to meet licensing requirements. Please consult your professional licensing organization for acceptance of this CE credit.

Commercial Support:

No commercial support was provided for accredited activities.

Participation Costs:

The cost to participate in these CE sessions is included in the meeting registration cost.

CME Inquiries:

For all CME related inquiries, please contact cds_support+pha@ pesgce.com.

Additional Information:

Additional information about this activity can be found at: PHAssociation.org/Education-Programs/Conference

How to Claim CE Credit

1. Go to the following URL: https://pha.cds.pesgce.com 2. Select the activity: 2018 Scientific Conference 3. Enter an e-mail address and password to begin setting up your profile or log in to an existing account 4. Verify, correct or add your information 5. Proceed and complete the activity evaluation for each session you attended 6. Upon completing your evaluations, you can print your CE certificate; your CE record will also be stored here for later retrieval 7. Please note that you must also complete an overall activity evaluation before you can print your CE certificate 8. If you are a pharmacist or pharmacy technician, your records will be reported directly to CPE Monitor 9. The website is open for completing your evaluation for 45 days after the event 10. After the website has closed, you can come back to the site at any time to print your certificate, but you will not be able to add any evaluations Please send any customer service requests to cds_ support+pha@pesgce.com.

PLANNING COMMITTEE DISCLOSURES

Vinicio A. de Jesus Perez, M.D., FCCP, FAHA is a selfmanaged stock shareholder in Actelion Pharmaceuticals Ltd., Gilead Sciences, Inc., Pfizer, Inc. and Eiger BioPharmaceuticals, Inc.

Christine Archer-Chicko, M.S.N., CRNP has served as a consultant, advisory board member or steering committee member for Actelion Pharmaceuticals Ltd.

Evan Brittain, M.D., M.Sc. has received investigator initiated research support from Gilead Sciences, Inc. Laura Duvall, PharmD, BCPS has nothing to disclose.

Jason Elinoff, M.D. has nothing to disclose.

Brian Graham, M.D., M.A. has received research or grant support from the National Institutes of Health. Rachel Hopper, M.D. has nothing to disclose.

Allyson Rupp, M.S.W., LCSW has served as a consultant, advisory board member or steering committee member for Actelion Pharmaceuticals Ltd., has served on a speaker’s bureau for Actelion Pharmaceuticals Ltd., and is an active faculty member for “Beyond the Basics” through Guidemark Health, sponsored by Actelion Pharmaceuticals Ltd.

Thenappan Thenappan, M.D. has served as a consultant, advisory board member or steering committee member for Actelion Pharmaceuticals Ltd. and Gilead Sciences, Inc. and has served on a speaker’s bureau for Medscape.

Tonya Zeiger, R.R.T., CPFT has nothing to disclose.

PHA staff and PESG staff planners and reviewers have no relevant financial interest to disclose.

FACULTY DISCLOSURES

Steven H. Abman, M.D. has received research or grant support from United Therapeutics Corporation.

Rana Awdish, M.D., FCCP has nothing to disclose.

Raymond L. Benza, M.D., FACC has received research or grant support from Actelion Pharmaceuticals Ltd., United Therapeutics Corporation, Bellerophon Therapeutics and Abbott.

Erika S. Berman Rosenzweig, M.D. has received research or grant support from Actelion Pharmaceuticals Ltd., Gilead Sciences, Inc., Bayer HealthCare Pharmaceuticals LLC, United Therapeutics Corporation and Lung Biotechnology PBC. Sangeeta M. Bhorade, M.D. has nothing to disclose.

Harm Bogaard, M.D. has nothing to disclose.

Gerilynn Connors, B.S., R.R.T., MAACVPR has nothing to disclose.

Ramona Doyle, M.D., M.Sc. is a self-managed stock shareholder in Roche Pharma and Gilead Sciences, Inc. Greg Elliott, M.D., MACP has served as a consultant, advisory board member or steering committee member for Bayer HealthCare Pharmaceuticals LLC and Bellerophon Therapeutics, has received research or grant support from Intermountain Research & Medical Foundation/Intermountain Healthcare, and Actelion Pharmaceuticals Ltd. David B. Frank, M.D., Ph.D. has nothing to disclose.

Elena Goncharova, Ph.D. has received research or grant support from Regeneron Pharmaceuticals.

Stephanie Siehr Handler, M.D. has nothing to disclose.

Anna Hemnes, M.D. has served as a consultant, advisory board member or steering committee member for Acceleron Pharma, Inc., Actelion Pharmaceuticals Ltd., Bayer HealthCare Pharmaceuticals LLC and United Therapeutics Corporation, and has received corporation grants from the National Institutes of Health and The Cardiovascular Medical Research Fund.

Dunbar Ivy, M.D. has served as a consultant, advisory board member or steering committee member for Actelion Pharmaceuticals Ltd., Bayer HealthCare Pharmaceuticals LLC, Eli Lilly and Company and United Therapeutics Corporation; has received research or grant support from Actelion Pharmaceuticals Ltd., United Therapeutics Corporation, Eli Lilly and Company, Bayer HealthCare Pharmaceuticals LLC, the National Institutes of Health and U.S. Food and Drug Administration; and is also a Board member of the Association for Pediatric Pulmonary Hypertension.

Steven M. Kawut, M.D., M.S. has nothing to disclose.

FACULTY DISCLOSURES (CONTINUED)

Tim Lahm, M.D. has served as a consultant, advisory board member or steering committee member for Actelion Pharmaceuticals Ltd. and Gilead Sciences, Inc., has served on a speaker’s bureau for Bayer HealthCare Pharmaceuticals LLC, and has received research or grant support from Eli Lilly and Company.

Deborah J. Levine, M.D. has nothing to disclose.

Sagar Lonial, M.D., FACP has served as a consultant, advisory board member or steering committee member for Amgen, Inc., Bristol-Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Pharmaceutica NV, Merck & Co., Inc., Novartis Pharmaceuticals and Takeda Pharmaceutical Company Ltd.

Dana McGlothlin, M.D. has nothing to disclose.

Mary P. Mullen, M.D., Ph.D. has nothing to disclose.

Roxane Paulin, Ph.D. has nothing to disclose.

Marlene Rabinovitch, M.D. has served as a consultant, advisory board member or steering committee member for Acceleron Pharma, Inc., Pfizer, Inc. and Calibr.

Josanna Rodriguez-Lopez, M.D. has received research or grant support from Actelion Pharmaceuticals Ltd.

Zeenat Safdar, M.D., M.S., FCCP has served as a consultant, advisory board member or steering committee member for Actelion Pharmaceuticals Ltd., Bayer HealthCare Pharmaceuticals LLC, Boehringer Ingelheim, Genentech, Inc., United Therapeutics Corporation and Gilead Sciences, Inc., and has served on a speaker’s bureau for Actelion Pharmaceuticals Ltd., Bayer HealthCare Pharmaceuticals LLC, Genentech, Inc., Boehringer Ingelheim, United Therapeutics Corporation and Gilead Sciences, Inc.

Oksana A. Shlobin, M.D. has served as a consultant, advisory board member or steering committee member for Actelion Pharmaceuticals Ltd., Bayer HealthCare Pharmaceuticals LLC, United Therapeutics Corporation and Lung Rx, LLC and has served on a speaker’s bureau for Actelion Pharmaceuticals Ltd., Bayer HealthCare Pharmaceuticals LLC, Lung Rx, LLC and United Therapeutics Corporation. Michael Snyder, Ph.D. has served as a consultant, advisory board member or steering committee member for Personalis, SensOmics, Qbio, January, Genapsys, Fitricine and Epinomics, has served on a speaker’s bureau for Illumina and Merck (pending), has received research or grant support from the National Institutes of Health, and is a co-founder of Personalis, SensOmics, Qbio, January and Fitricine.

Namita Sood, M.D., FCCP has served on a speaker’s bureau for Gilead Sciences, Inc.

Norman Stockbridge, M.D., Ph.D. has nothing to disclose.

Fernando Torres, M.D. has served as a consultant, advisory board member or steering committee member for Bayer HealthCare Pharmaceuticals LLC, Gilead Sciences, Inc., Actelion Pharmaceuticals Ltd., SteadyMed Therapeutics, Inc., Reata Pharmaceuticals, Inc. and Arena Pharmaceuticals, Inc., has served on a speaker’s bureau for Bayer HealthCare Pharmaceuticals LLC, Actelion Pharmaceuticals Ltd. and Reata Pharmaceuticals, Inc., and has received research or grant support from Gilead Sciences, Inc., United Therapeutics Corporation, Medtronic, GeNO, LLC, the National Institutes of Health, Eiger BioPharmaceuticals, Inc. and Bellerophon Therapeutics. Uyen T. Truong, M.D. has nothing to disclose.

Corey E. Ventetuolo, M.D., M.S. has served as a consultant, advisory board member or steering committee member for Acceleron Pharma, Inc., Bayer HealthCare Pharmaceuticals LLC and United Therapeutics Corporation, has received research or grant support from Actelion Pharmaceuticals Ltd. and Eiger BioPharmaceuticals, Inc. and her spouse is an employee of CVS Health.

Timothy L. Williamson, M.D. has received research or grant support from United Therapeutics Corporation, Reata Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals LLC and Liquidia Technologies.

Roham T. Zamanian, M.D., FCCP has served as a consultant, advisory board member or steering committee member for Actelion Pharmaceuticals Ltd., Vivus and Eiger BioPharmaceuticals, Inc., has received research or grant support from Actelion Pharmaceuticals Ltd., United Therapeutics Corporation and Lung Rx, LLC, and is a self-managed stock shareholder in Selten Pharmaceuticals.

For a full list of conflict of interest disclosures submitted and resolved for the 2018 PHA Scientific Sessions poster presenters, visit: PHAssociation.org/2018-Conference-Poster-Hall-Disclosures.

ABSTRACT WINNERS AND PRESENTATIONS

Poster Hall Session

Thursday, June 28 4:30 – 7:30 p.m.

At the conclusion of this session, participants will be able to: • Understand the contribution of genetic mutations, protein expression and inflammation to PH pathogenesis and progression • Discuss the role and utility of novel diagnostic strategies in the diagnosis of PH • Understand the efficacy of PH-targeted therapies currently in early phase clinical trials and effectiveness of approved therapies through interpretation of data from post-marketing studies • Analyze interclass and intraclass treatment modality transitions in patients with pulmonary arterial hypertension The following top ten abstracts will be presented during the Poster Hall Session. PHA congratulates the winners of the awards for best abstracts in basic and clinical science chosen by the 2018 PHA Scientific Sessions Committee.

Basic Science – Category Winner

5:30 – 5:40 p.m. Presenting Author:

Zhiyu Dai, Ph.D.

1004 Endothelial and Smooth Muscle Cell Interaction Via FoxM1 Mediates Vascular Remodeling and Pulmonary Arterial Hypertension

Dai Z, Zhu MM, Peng Y, Jin H, Machireddy N, Qian Z, Zhang X, Zhao YY Northwestern University, Chicago, IL, USA

Basic Science – Runner-up

5:40 – 5:50 p.m. Presenting Author:

Ekaterina Legchenko, Ph.D. 1012 2018 PHA Scientific Sessions and Education for Medical The PPARγ Agonist Pioglitazone Reverses Pulmonary Arterial Hypertension Professionals and Prevents Right Heart Failure Through Fatty Acid Oxidation

Legchenko E1, Chouvarine P1, Borchert P1, Fernandez-Gonzalez A2, Snay E3, Mägel L4 , Mitsialis SA2, Meier M5, Rog-Zielinska E6, Kourembanas S2, Jonigk D4, Hansmann G1 1Department of Pediatric Cardiology and Critical Care, and Pulmonary Vascular Research Center (PVRC), Hannover Medical School, Germany, 2Division of Newborn Medicine, Department of Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA, 3Division of Nuclear Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA, 4Institute of Pathology, Hannover Medical School, Hannover, Germany; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Hannover, Germany; The German Center for Lung Research (Deutsches Zentrum für Lungenforschung DZL), 5Institute of Laboratory Animal Science, Hannover Medical School, Hannover, Germany, 6Institute for Experimental Cardiovascular Medicine, Freiburg, Germany, 7Actelion Pharmaceuticals US, Inc., South San Francisco, CA, USA, 8Boston University School of Medicine, Boston, MA, USA

Clinical Science – Category Winner

5:50 – 6 p.m. Presenting Author:

Geoffrey A. Bocobo, B.Sc. 1031 Bone Morphogenetic Protein 9 is a Mechanistic Biomarker of Portopulmonary Hypertension

Nikolic I1, Yung LM1, Yang P1, Malhotra R2, Paskin-Flerlage SD1, Dinter T1, Bocobo GA1 , McNeil M1, Faugno AJ3, Lai CSC1, Upton PD4, Goumans MJ5, Zamanian RT6, Elliott G7 , Morrell NW4, Chung RT8, Channick RW9, Roberts KE3, Yu PB1 1Brigham and Women’s Hospital and Harvard Medical School, Division of Cardiovascular Medicine, Department of Medicine, Boston, MA, USA, 2Massachusetts General Hospital and Harvard Medical School, Division of Cardiology, Department of Medicine, Boston, MA, USA, 3Tufts Medical Center, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Boston, MA, USA, 4University of Cambridge School of Clinical Medicine, Addenbrooke’s and Papworth Hospitals, Division of Respiratory Medicine, Department of Medicine, Cambridge, United Kingdom, 5Leiden University Medical Centre, Department of Molecular Cell Biology and Cancer Genomics Centre Netherlands, Leiden, Netherlands, 6Stanford University Medical Center, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford, CA, USA, 7Intermountain Medical Center and University of Utah, Department of Medicine, Salt Lake City, UT, USA, 8Massachusetts General Hospital and Harvard Medical School, Gastrointestinal Unit and Liver Center, Department of Medicine, Boston, MA, USA, 9Massachusetts General Hospital and Harvard Medical School, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Boston, MA, USA